No material news briefings were available in the provided context for Gilead Sciences Inc. (GILD) as of the generation date of 2026-08-05. The report is therefore based on verified financial filings, insider transaction records, and macroeconomic data cited below.
Gilead Sciences reported trailing twelve-month revenue of $29.74 billion as of 2026-03-31, representing year-over-year growth of approximately 4.4% [SEC 10-Q - GILD - 2026-03-31]. Net income for the same period stood at $9.22 billion, yielding a net margin of approximately 31.0%. Gross margin was recorded at 66.5% and operating margin at 34.9%. Earnings per share grew 54.8% year-over-year on a TTM basis. The company held $7.63 billion in cash against total debt of $23.49 billion. Market capitalisation was approximately $167.98 billion, with a price-to-earnings ratio of 18.4 [SEC 10-Q - GILD - 2026-03-31].
Insider activity was the primary trigger for this report. Five insider transactions were recorded in August 2026, with a net direction of selling and a combined net value of approximately -$2.73 million [SEC Form 4 - GILD - 2026-08]. No institutional 13F filing data was provided in the current context; accordingly, no changes to notable holdings positions are cited here.
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield (DGS10) at 4.70% and the 2-year yield (DGS2) at 4.25%, producing a normal yield curve spread of 45 basis points [FRED DGS10] [FRED DGS2]. This rate configuration represents the broader fixed-income backdrop against which Gilead's debt profile of $23.49 billion is contextualised [SEC 10-Q - GILD - 2026-03-31].